Objectives

• Conduct full-cycle national radiation-related medical and biological studies from basic study to clinical trial, such as improvement of radiotherapy efficiency, impact of radiation on the human body, and side effects of radiotherapy

Research Areas

• Conduct study on resistance to radiotherapy and develop technologies to increase radiotherapy
• Discover radiation-sensitive biomarkers and treatment reaction indicators
• Conduct study on response to and recovery from biomarker and gene damage by radiation
• Discover radiation-specific anti-cancer target and radiation-sensitive substances
• Develop radio-immunomodulator
• Conduct study on the side effects of radiotherapy
• Conduct study on the impact of low-dose radiation on the human body

Research Outcomes

• Development of β-apopicropodophyllin, a Candidate for New Anticancer Drug and for Radiotherapy Promotion, and Its Derivatives
  • Verified the combined treatment effect of β-apopicropodophyllin on lung cancer and colorectal cancer cell lines, transferred technology to JNC Science (2018, 2019)
  • Won the Trade, Industry, and Energy Minister’s Award at the Korea Invention Patent Exhibition 2021 (patent)
  • Developed the world’s first new synthetic substance (JNC-1043) (2021), conducting non-clinical trial for and commercializing new anti-cancer drug and radiotherapy enhancer
• Development of radiotherapy candidate containing Aripiprazole
  • Won the Korean Intellectual Property Office Commissioner’s Award at the Korea Invention Patent Exhibition 2019 (technology transfer performance)
  • Radiosensitizer Technology Transfer in 2019: VS PharmTech
  • Obtained approval for radiosensitizer clinical trial (first in Korea)
  • Commercialization in progress through follow-up study of technology transfer
    • May 24, 2021: IND application for phase 1 clinical trial targeting head and neck cancer
    • Oct. 8, 2021: Approval for phase 1 clinical trial from the Ministry of Food and Drug Safety
    • Currently entering phase 1.5
• Development of anti-cancer drug that increases the effect of cancer treatment through cancer cell-targeted attach by combining specific protein to herpes virus
  • Established “Gencellmed,” the No. 1 venture company of the Korea Institute of Radiological & Medical Sciences for new drug development (Jun. 2018)
  • Completed investment inducement of KRW 3 billion, promoting additional investment (Jun. 2022)
• Development of new breast cancer and radiation-targeted anti-cancer drug candidate technology
  • Transferred technology to DL Pharma (2020)
  • *MASTL inhibitor portfolio, contract on Feb. 19, 2020
  • Scheduled to promote technology transfer to and joint commercialization with pharmaceutical companies for first-in class innovative anticancer drug and intractable breast cancer-targeted drug, follow-up study in progress (2022)
• Development of radiosensitizer composition for cancer treatment using artificial intelligence
  • Overcame limitations in new anti-cancer radiation drug development, discovered new targeted drug candidate with high efficiency and at low cost by using artificial intelligence new drug development technologies, and transferred technology to PharmCADD (2021)
  • Conducted study on the acceleration of new drug development through cooperation with pharmaceutical companies using quantum-based artificial intelligence, pre-clinical animal test through synthesis of related derivatives in progress
• Development of low-molecular cancer immunotherapy agent for combined use with radiotherapy through cooperation with innovative pharmaceutical companies
  • Conducting a study on the extension of applications for combined radiotherapy drug targeting initial new drugs (TRL 6 - 7, phase 1 clinical drug) based on cooperation with innovative pharmaceutical companies
  • Verified effect of cancer immunotherapy on combined radiotherapy using BR101801, an immune cell modulating factor-targeted new drug candidate (Dec. 2021),Developed combined solid tumor radiotherapy drug with hematological malignancy drug
    • *Study outcome published in top 5% journal in the chemotherapy field (JITC) (IF: 13.751)
    • Generation of immune suppressor cells reduced when radiotherapy and targeted chemotherapy were concurrently administered, verified the effect of full-body cancer immunotherapy to remove metastatic cancer as well (Mar. 2022)
  • Developed combined radiotherapy drug with STP1002 colorectal cancer-targeted drug (STPHARM)
    • *Study outcome published in top 10% journal in the chemotherapy field (EJC Positive Revision) (IF: 9.162)
• Development of Radiation Pulmonary Fibrosis Control Drug
  • Pulmonary fibrosis control drug superior to clinically approved drug for idiopathic pulmonary fibrosis drug, expected to be used in overcoming vascular resistance in radiotherapy
    • Registered patent for radiation pulmonary fibrosis control drug, transferred technology to ONCOBIX (2019)
    • * Result of efficacy test as pulmonary fibrosis treatment candidate
    • * Use in radiation damage protection/alleviation and prevention or treatment of pulmonary fibrosis, transferred technology to J2H BIOTECH (2021)
    • * Result of Study on Radiation Pulmonary Fibrosis Control Effect: Contract concluded on Nov. 18, 2021
• Development of Drug to Control Radiation Cardiac Damage and Cardiotoxicity of Anticancer drugs
  • Verified cardiovascular damage caused by and cardiotoxicity mechanism of radiation using vascular-specific genetically engineered animal model, confirmed the effect of the derived radiation cardiovascular damage- inhibiting antibody to lower cardiac damage
    • Scheduled to promote follow-up studies and joint commercialization through cooperation with pharmaceutical companies
    • *Study outcome published in top 5% journal (Nature Communications, 2021) (IF: 14.919)